Molecular mechanisms of aromatase inhibition by new A, D-ring modified steroids

Biological Chemistry

Volumn 389, Issue 9, 2008, Pages 1183-1191

  Cepa, Margarida ^a,b   Correia Da Silva, Georgina ^a,b   Tavares Da Silva, Elisiario J ^c   Roleira, Fernanda M F ^c   Hong, Yanyan ^d   Chen, Shiuan ^d   Teixeira, Natercia A ^a,b  

^a UNIVERSITY OF PORTO   (Portugal)

^b UNIVERSITY OF PORTO   (Portugal)

^c UNIVERSITY OF COIMBRA   (Portugal)

^d CITY OF HOPE NATIONAL MEDICAL CENTER   (United States)

Author keywords

Aromatase inhibitors; Breast cancer; Cell lines; Computer assisted protein docking; Site directed mutagenesis studies

Indexed keywords

3ALPHA,4ALPHA EPOXY 5ALPHA ANDROSTAN 17 ONE; 5ALPHA ANDROST 3 EN 17 ONE; AROMATASE; AROMATASE INHIBITOR; STEROID; UNCLASSIFIED DRUG; MUTANT PROTEIN;

ARTICLE; CELL PROLIFERATION; CONTROLLED STUDY; DOSE RESPONSE; DRUG INHIBITION; DRUG MECHANISM; DRUG STRUCTURE; ENZYME INHIBITION; HUMAN; HUMAN CELL; PRIORITY JOURNAL; PROTEIN EXPRESSION; SITE DIRECTED MUTAGENESIS; BINDING SITE; BREAST TUMOR; CHEMISTRY; FEMALE; METABOLISM; TUMOR CELL LINE;

AROMATASE; AROMATASE INHIBITORS; BINDING SITES; BREAST NEOPLASMS; CELL LINE, TUMOR; CELL PROLIFERATION; FEMALE; HUMANS; MUTAGENESIS, SITE-DIRECTED; MUTANT PROTEINS; STEROIDS;

EID: 49749135814     PISSN: 14316730     EISSN: 14374315     Source Type: Journal    
DOI: 10.1515/BC.2008.134     Document Type: Article

References (40)

1. Ackerman, G.E., Smith, M.E., Mendelson, C.R., MacDonald, P.C., and Simpson, E.R. (1981). Aromatization of androstenedione by human adipose tissue stromal cells in monolayer culture. J. Clin. Endocrinol. Metab. 53, 412-417.
2. Ali, S. and Coombes, R.C. (2002). Endocrine-responsive cancer and strategies for combating resistance. Nat. Rev. Cancer 2, 101-115.
3. Bates, S.E., Davidson, N.E., Valverius, E.M., Freter, C.E., Dickson, R.B., Tam, J.P., Kudlow, J.E., Lippman, M.E., and Salomon, D.S. (1988). Expression of transforming growth factor a and its messenger ribonucleic acid in human breast cancer: its regulation by estrogen and its possible functional significance. Mol. Endocrinol. 2, 543-555.
4. Berthois, Y., Katzenellenbogen, J.A., and Katzenellenbogen,B.S. (1986). Phenol red in tissue culture media is a weak estrogen: implications concerning the study of estrogen-responsive cells in culture. Proc. Natl. Acad. Sci. USA 83, 2496-2500.
5. Brodie, A.M., Banks, P.K., Inkster, S.E., Dowsett, M., and Coombes, R.C. (1990). Aromatase inhibitors and hormonedependent cancers. J. Steroid Biochem. Mol. Biol. 37, 327-333.
6. Brueggemeier, R.W. (2006). Update on the use of aromatase inhibitors in breast cancer. Expert Opin. Pharmacother. 7, 1919-1930.
7. Brueggemeier, R.W. and Katlic, N.E. (1990). Aromatase inhibition by an enzyme-activated irreversible inhibitor in human carcinoma cell cultures. Cancer Res. 50, 3652-3656.
8. Bulun, S.E., Price, T.M., Aikten, J., Mahendro, M.S., and Simpson, E. (1993). A link between breast cancer and local estrogen biosynthesis suggested by quantification of breast adipose tissue aromatase cytochrome P450 transcripts using competitive polymerase chain reaction after reverse transcription. J. Clin. Endocrinol. Metab. 77, 1622-1628.
9. Cepa, M., Tavares da Silva, E., Correia-da-Silva, G., Roleira, F., and Teixeira, N.A. (2005). Structure-activity relationships of new A, D-ring modified steroids as aromatase inhibitors. Design, synthesis and biological activity evaluation. J. Med. Chem. 48, 6379-6385.
10. Ellis, M.J., Coop, A., Singh, B., Tao, Y., Llombart-Cussac, A., Janicke, F., Mauriac, L., Quebe-Fehling, E., Chaudri-Ross, H.A., Evans, D.B., et al. (2003). Letrozole inhibits tumor proliferation more effectively than tamoxifen independent of HER1/2 expression status. Cancer Res. 63, 6523-6531.
11. Esteban, J.M., Warsi, Z., Haniu, M., Hall, P., Shively, J.E., and Chen, S. (1992). Detection of intratumoral aromatase in breast carcinomas. An immunohistochemical study with clinicopathologic correlation. Am. J. Pathol. 140, 337-343.
12. Favia, A.D., Cavalli, A., Masetti, M., Carotti, A., and Recanatini, M. (2006). Three-dimensional model of the human aromatase enzyme and density functional parameterization of the ironcontaining protoporphyrin IX for a molecular dynamics study of heme-cysteinato cytochromes. Proteins 62, 1074-1087.
13. Green, S.J. (1990). Steroid receptors and new (anti-) steroidal agents: modulation of estrogen receptor activity by estrogens and anti-estrogens. J. Steroid Biochem. Mol. Biol. 37, 747-751.
14. Hemsell, D.L., Grodin, J., and Breuner, P.F. (1974). Plasma precursors of estrogen. II. Correlation of the extent of conversion of plasma androstenedione to estrone with age. J. Clin. Endocrinol. Metab. 38, 476-479.
15. Hong, Y., Yu, B., Sherman, M., Yuan, Y.C., Zhou, D., and Chen, S. (2007). Molecular basis for the aromatization reaction and exemestane-mediated irreversible inhibition of human aromatase. Mol. Endocrinol. 21, 401-414.
16. Kadohama, N., Yarborough, C., Zhou, D., and Chen, S. (1992). Kinetic properties of aromatase mutants Pro308Phe, Asp309Asn, and Asp309Ala, and their interactions with aromatase inhibitors. J. Steroid Biochem. Mol. Biol. 43, 693-701.
17. Kao, Y.C., Korzekwa, K.R., Laughton, C.A., and Chen, S. (2001). Evaluation of the mechanism of aromatase cytochrome P450. A site-directed mutagenesis study. Eur. J. Biochem. 268, 243-251.
18. Kijima, I., Itoh, T., and Chen, S. (2005). Growth inhibition of estrogen receptor-positive and aromatase-positive human breast cancer cells in monolayer and spheroid cultures by letrozole, anastrozole, and tamoxifen. J. Steroid Biochem. Mol. Biol. 97, 360-368.
19. Lippman, M.E., Dickson, R.B., Kasid, A., Gelmann, E., Davidson, N., McManaway, M., Huff, K., Bronzert, D., Bates, S., and Swain, S. (1986). Autocrine and paracrine growth regulation of human breast cancer. J. Steroid Biochem. 24, 147-154.
20. Lu, Q., Nakmura, J., Savinov, A., Yue, W., Weisz, J., Dabbs, D.J., Wolz, G., and Brodie, A. (1996). Expression of aromatase protein and messenger ribonucleic acid in tumor epithelial cells and evidence of functional significance of locally produced estrogen in human breast cancers. Endocrinology 137, 3061-3068.
21. Miller, W.R., Anderson, T.J., and Jack, W.J.L. (1990). Relationship between tumor aromatase activity, tumor characteristics and response to therapy. J. Steroid Biochem. Mol. Biol. 37, 537-548.
22. Miller, W.R., Dixon, J.M., Cameron, D.A., and Anderson, T.J. (2001). Biological and clinical effects of aromatase inhibitors in neoadjuvant therapy. J. Steroid Biochem. Mol. Biol. 79, 103-107.
23. Mouridsen, H., Gershanovich, M., Sun, Y., Perez-Carrion, R., Boni, C., Monnier, A., Apffelstaedt, J., Smith, R., Sleeboom, H.P., Janicke, F., et al. (2001). Superior efficacy of letrozole versus tamoxifen as first-line therapy for postmenopausal women with advanced breast cancer: results of a phase III study of the International Letrozole Breast Cancer Group. J. Clin. Oncol. 19, 2596-2606.
24. Nabholtz, J.M., Buzdar, A., Pollak, M., Harwin, W., Burton, G., Mangalik, A., Steinberg, M., Webster, A., and von Euler, M. (2000). Anastrozole is superior to tamoxifen as first-line therapy for advanced breast cancer in postmenopausal women: results of a North American multicenter randomized trial. Arimidex Study Group. J. Clin. Oncol. 18, 3758-3767.
25. Nabholtz, J.M., Bonneterre, J., Buzdar, A., Robertson, J.F., and Thurlimann, B. (2003). Anastrozole (Arimidex) versus tamoxifen as first-line therapy for advanced breast cancer in postmenopausal women: survival analysis and updated safety results. Eur. J. Cancer 39, 1684-1689.
26. Nagaoka, M., Watari, Y., Yajima, H., Tsukioka, K., Muroi, Y., Yamada, K., and Numazawa, M. (2003). Structure-activity relationships of 3-deoxy androgens as aromatase inhibitors. Synthesis and biochemical studies of 4-substituted 4-Ene and 5-Ene steroids. Steroids 68, 533-542.
27. Numazawa, M. and Yamaguchi, S. (1999). Synthesis and structure-activity relationships of 6-phenylaliphatic-substituted C19 steroids having a 1,4-diene, 4,6-diene or 1,4,6-triene structure as aromatase inhibitors. Steroids 64, 187-196.
28. Numazawa, M., Yamada, K., Nitta, S., Sasaki, C., and Kidokoro, K. (2001). Role of hydrophilic interaction in binding of hydroxylated 3-deoxy C(19) steroids to the active site of aromatase. J. Med. Chem. 44, 4277-4283.
29. Numazawa, M., Yoshimura, A., Watari, Y., and Matsuzaki, H. (2002). Aromatase inhibition by 4b,5b-epoxides of 16 a-hydroxyandrostenedione and its 19-oxygenated analogs, potential precursors of estriol production in the feto-placental unit. Biol. Pharm. Bull. 25, 1566-1569.
30. Numazawa, M., Nagaoka, M., and Sohtome, N. (2005). Aromatase reaction of 3-deoxyandrogens: steric mode of the C-19 oxygenation and cleavage of the C10-C19 bond by human placental aromatase. Biochemistry 44, 10839-10845.
31. Santen, R.J. and Harvey, H.A. (1999). Use of aromatase inhibitors in breast carcinoma. Endocr. Relat. Cancer 6, 75-92.
32. Santen, R.J., Martel, J., Hoagland, M., Naftolin, F., Roa, L., Har-ada, N., Hafer, L., Zaino, R., and Santner, S.J. (1994). Stromal spindle cells contain aromatase in human breast tumors. J. Clin. Endocrinol. Metab. 79, 627-632.
33. Sasano, H., Nagura, H., Harada, N., Goukon, Y., and Kimura, M. (1994). Immunolocalization of aromatase and other steroidogenic enzymes in human breast disorders. Hum. Pathol. 25, 530-535.
34. Simpson, E.R. (2003). Sources of estrogen and their importance. J. Steroid Biochem. Mol. Biol. 86, 225-230.
35. Tavares da Silva, E.J., Roleira, F., Sá e Melo, M.L., Neves, A.S., Paixao, J.A., Almeida, M.J., Silva, M.R., and Andrade, L.C. (2002). X-ray and deuterium labeling studies on the abnormal ring cleavages of a 5 b-epoxide precursor of formestane. Steroids 67, 311-319.
36. Thompson, E.A. and Siiteri, P.K. (1974). Utilization of oxygen and reduced nicotinamide adenine dinucleotide phosphate by human placental microsomes during aromatization of androstenedione. J. Biol. Chem. 249, 53-64.
37. Winer, E.P., Hudis, C., Burstein, H.J., Chebowski, R.T., Ingle, J.N., Edge, S.B., Mamounas, E.P., Gralow, J., Goldstein, L.J., Pritchard, K.I., et al. (2002). Technology assessment on the use of aromatase inhibitors as adjuvant therapy for women with hormone receptor-positive breast cancer: Status Report 2002. J. Clin. Oncol. 20, 3317-3327.
38. Zhou, D.J., Pompon, D., and Chen, S.A. (1990). Stable expression of human aromatase complementary DNA in mammalian cells: a useful system for aromatase inhibitor screening. Cancer Res. 50, 6949-6954.
39. Zhou, D.J., Korzekwa, K.R., Poulos, T., and Chen, S. (1992). A site-directed mutagenesis study of human placental aromatase. J. Biol. Chem. 267, 762-768.
40. Zumoff, B. (1998). Does postmenopausal estrogen administration increase the risk of breast cancer? Contributions of animal, biochemical and clinical investigative studies to a resolution of the controversy. Proc. Soc. Exp. Biol. Med. 217, 30-37.